Table 1.
The clinicopathologic characteristics of patients in the training and validation cohorts
| Parameter | Training cohort | Validation cohort | p value |
|---|---|---|---|
| (n = 370) | (n = 146) | ||
| Gender: female/male (n) | 48/322 | 21/125 | 0.104 |
| Age (years) | 51.74 ± 11.77 | 50.78 ± 10.89 | 0.261 |
| HBsAg: negative/positive (n) | 54/306 | 28/118 | 0.248 |
| Family history: absent/present (n) | 332 /38 | 124/22 | 0.126 |
| Drinking: absent/present (n) | 212/158 | 75/71 | 0.222 |
| Smoking: absent/present (n) | 218/152 | 88/58 | 0.778 |
| Cirrhosis: absent/present (n) | 34/336 | 11/135 | 0.548 |
| MVI: absent/present (n) | 280/90 | 117/29 | 0.279 |
| NEUT (×109/L) | 3.90 ± 1.93 | 4.10 ± 2.36 | 0.436 |
| LYMPH (×109/L) | 1.69 ± 0.61 | 1.66 ± 0.62 | 0.057 |
| Platelets (×109/L) | 186.33 ± 86.03 | 183.56 ± 78.82 | < 0.001* |
| GGT (U/L) | 106.97 ± 120.92 | 104.40 ± 109.25 | < 0.001* |
| LDH (U/L) | 215.43 ± 95.46 | 204.79 ± 90.36 | 0.113 |
| Tumor size (cm) | 7.65 ± 4.54 | 7.97 ± 4.84 | 0.140 |
| Tumor number: single/multiple (n) | 280/50 | 108/38 | 0.239 |
| Grade: G1/G2/G3 (n) | 54/211/105 | 27/100/19 | < 0.001* |
| LNM: absent/present (n) | 10/360 | 7/139 | 0.230 |
| Child-Pugh stage: A/B (n) | 328/42 | 131/15 | 0.725 |
| AFP ≤ 20/ > 20 (ng/mL) | 130/240 | 53/93 | < 0.001* |
| NLR | 2.63 ± 2.17 | 2.81 ± 2.01 | 0.028* |
| GLR | 74.86 ± 99.5 | 73.51 ± 82.8 | 0.115 |
| GMWG | 23.50 ± 12.32 | 23.6 ± 12.06 | 0.301 |
Abbreviations: n number of patients, HBsAg hepatitis B surface antigen, MVI microvascular invasion, NEUT neutrophil count, LYMPH lymphocyte count, GGT gamma-glutamyl transpeptidase, LDH lactate dehydrogenase, LNM lymph node metastasis, AFP alpha fetoprotein, NLR neutrophils to lymphocytes ratio, GLR gamma-glutamyl transpeptidase to lymphocyte count ratio, GMWG geometric mean of gamma-glutamyl transferase and white blood cell
*p-value indicates statistically significant